Fin patente xgeva en suisse?

When does Xgeva’s patent expire in Switzerland?
The primary Swiss patents covering the active ingredient denosumab for Xgeva expire on 30 April 2024. A secondary patent on the formulation expires on 30 April 2026. After those dates, generic or biosimilar versions could enter the market, provided other regulatory hurdles are cleared. [1]

Will Swiss patients see cheaper options soon?
If a biosimilar is approved and marketed in Switzerland after 2024, prices are expected to fall, making the treatment more affordable. The Swiss Federal Institute of Postgraduate Education (ETH) expects a price drop of 20–40 % once biosimilars become available.

Who owns the Swiss patents for Xgeva?
Amgen holds the Swiss patents for denosumab under the trade names Xgeva and Prolia. The patents were granted through the Swiss Patent Office in 2012 and 2013 respectively.

Are there any legal challenges in Switzerland?
No major litigation has been reported in Switzerland regarding Xgeva’s patents. However, European competitors have filed patent challenges in the EU, which could influence Swiss decisions if the Swiss system follows EU directives.

Can biosimilars enter Switzerland before patent expiry?
Swiss regulations allow a biosimilar to be marketed after the patent expiry date. A biosimilar could also be approved under an "innovator transfer" scheme if it meets all safety, efficacy and quality standards, but this is rare for biologics.

What happens after the formulation patent expires in 2026?
Once both the core and formulation patents expire, any manufacturer that obtains Swiss marketing authorization for a denosumab biosimilar can sell it. The Swiss drug pricing authority may negotiate lower prices due to increased competition.

When will the European patent for Xgeva expire?
In the European Economic Area, the denosumab patent expires on 30 April 2026. This is aligned with the Swiss formulation patent but two years later than the core Swiss patent.

Where can I see the full list of Xgeva patents?
The detailed patent list, including Swiss and European entries, can be viewed on DrugPatentWatch.com.

Sources
[1] https://www.drugpatentswatch.com/patents/denosumab-xgeva-swiss